Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736

Valentina Restelli; Rosaria Chilà; Monica Lupi; Andrea Rinaldi; Ivo Kwee; Francesco Bertoni; Giovanna Damia; Laura Carrassa

doi:10.18632/oncotarget.5954

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736

Valentina Restelli _, Rosaria Chilà, Monica Lupi, Andrea Rinaldi, Ivo Kwee, Francesco Bertoni, Giovanna Damia and Laura Carrassa

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:37229-37240. https://doi.org/10.18632/oncotarget.5954

Metrics: PDF 2020 views | HTML 2193 views | ?

Abstract

Valentina Restelli1, Rosaria Chilà1, Monica Lupi1, Andrea Rinaldi2, Ivo Kwee2,3,4, Francesco Bertoni2,5, Giovanna Damia1 and Laura Carrassa1

1 Laboratory of Molecular Pharmacology and Laboratory of Cancer Pharmacology, Department of Oncology, IRCCS- Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy

2 Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland

3 Dalle Molle Institute for Artificial Intelligence (IDSIA), Manno, Switzerland

4 Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland

5 Lymphoma Unit, IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Correspondence to:

Laura Carrassa, email:

Giovanna Damia, email:

Keywords: Chk1, cyclin D1, mantle cell lymphoma, targeted therapy, mechanisms of resistance

Received: June 17, 2015 Accepted: September 17, 2015 Published: October 02, 2015

Abstract

Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma characterized by the chromosomal translocation t(11;14) that leads to constitutive expression of cyclin D1, a master regulator of the G1-S phase. Chk1 inhibitors have been recently shown to be strongly effective as single agents in MCL. To investigate molecular mechanisms at the basis of Chk1 inhibitor activity, a MCL cell line resistant to the Chk1 inhibitor PF-00477736 (JEKO-1 R) was obtained and characterized. The JEKO-1 R cell line was cross resistant to another Chk1 inhibitor (AZD-7762) and to the Wee1 inhibitor MK-1775. It displayed a shorter doubling time than parental cell line, likely due to a faster S phase. Cyclin D1 expression levels were decreased in resistant cell line and its re-overexpression partially re-established PF-00477736 sensitivity. Gene expression profiling showed an enrichment in gene sets involved in pro-survival pathways in JEKO-1 R. Dasatinib treatment partly restored PF-00477736 sensitivity in resistant cells suggesting that the pharmacological interference of pro-survival pathways can overcome the resistance to Chk1 inhibitors. These data further corroborate the involvement of the t(11;14) in cellular sensitivity to Chk1 inhibitors, fostering the clinical testing of Chk1 inhibitors as single agents in MCL.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5954

Publication Alerts

Research Papers:

Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736

Abstract